- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00935350
Reduction of the Glycemic Index by a Novel Viscous Polysaccharide
July 8, 2009 updated by: Glycemic Index Laboratories, Inc
Effect of Adding the Novel Fiber, PGX®,to Commonly Consumed Foods on Glycemic Response and Glycemic Index: A Practical and Effective Strategy for Reducing Post Prandial Blood Glucose Levels.
Reductions of postprandial glucose levels have been demonstrated previously with the addition of a novel viscous polysaccharide (NVP) to a glucose drink and standard white bread.
This study explores whether these reductions are sustained when NVP is added to a range of commonly consumed foods.
Study Overview
Status
Completed
Conditions
Detailed Description
Recently, a commercial novel viscous polysaccharide (NVP)complex has been developed which is marketed in both the USA and Canada under the trade name PGX® (PolyGlycopleX) (InovoBiologic Inc, Calgary, AB, Canada).
This complex consists of three viscous non starch polysaccharides which are processed using proprietary technology (EnviroSimplex®) to produce compressed granules which delays the onset of viscosity and increases palatability of the fiber when added to food.
Previously, this fibre was shown to lower postprandial glucose levels in a dose responsive manner when mixed with a glucose drink and sprinkled onto a standard white bread demonstrating that the processing did not interfere with the effectiveness of the fiber.
From this study the reduction in GI was calculated to be 7 units per gram of NVP when added to a solid food, however it is not known whether this relationship would be maintained when the NVP was added to a range of commonly eaten foods.
This study therefore evaluates the effect of the addition or incorporation of NVP into a range of foods on postprandial glycemia and whether the reductions in glycemic index could be predicted using.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada
- Glycemic Index Laboratories, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- healthy individuals
- 18-75 years old
- BMI less than 35 kg/m2
Exclusion Criteria:
- Medications influencing gastrointestinal function
- Pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 1
Control White bread containing 50g available carbohydrate
|
2.5 grams of PGX
5.0 grams of PGX
0 grams of PGX
|
Placebo Comparator: 2
White bread and milk control
|
2.5 grams of PGX
5.0 grams of PGX
0 grams of PGX
|
Placebo Comparator: 3
Granola control
|
2.5 grams of PGX
5.0 grams of PGX
0 grams of PGX
|
Placebo Comparator: 4
Cornflakes and milk control
|
2.5 grams of PGX
5.0 grams of PGX
0 grams of PGX
|
Placebo Comparator: 5
White rice control
|
2.5 grams of PGX
5.0 grams of PGX
0 grams of PGX
|
Placebo Comparator: 6
Fruit yogurt control
|
2.5 grams of PGX
5.0 grams of PGX
0 grams of PGX
|
Placebo Comparator: 7
Turkey dinner control
|
2.5 grams of PGX
5.0 grams of PGX
0 grams of PGX
|
Experimental: 8
Granola
|
2.5 grams of PGX
5.0 grams of PGX
0 grams of PGX
|
Experimental: 9
Cornflakes and milk
|
2.5 grams of PGX
5.0 grams of PGX
0 grams of PGX
|
Experimental: 10
White Rice
|
2.5 grams of PGX
5.0 grams of PGX
0 grams of PGX
|
Experimental: 11
Fruit yogurt
|
2.5 grams of PGX
5.0 grams of PGX
0 grams of PGX
|
Experimental: 12
Turkey dinner
|
2.5 grams of PGX
5.0 grams of PGX
0 grams of PGX
|
Placebo Comparator: 13
White Bread
|
2.5 grams of PGX
5.0 grams of PGX
0 grams of PGX
|
Placebo Comparator: 14
White bread
|
2.5 grams of PGX
5.0 grams of PGX
0 grams of PGX
|
Experimental: 15
Granola
|
2.5 grams of PGX
5.0 grams of PGX
0 grams of PGX
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Relative Blood glucose response of food with and without NVP
Time Frame: Acute blood glucose response measured at 0, 15,30,45,60,90 and 120 min
|
Acute blood glucose response measured at 0, 15,30,45,60,90 and 120 min
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2006
Primary Completion (Actual)
June 1, 2006
Study Completion (Actual)
August 1, 2006
Study Registration Dates
First Submitted
March 25, 2009
First Submitted That Met QC Criteria
July 8, 2009
First Posted (Estimate)
July 9, 2009
Study Record Updates
Last Update Posted (Estimate)
July 9, 2009
Last Update Submitted That Met QC Criteria
July 8, 2009
Last Verified
July 1, 2009
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- GIL-6033
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Glucose, Postprandial
-
San Diego State UniversityCompletedPostprandial Blood GlucoseUnited States
-
Marjukka KolehmainenCompletedHyperglycemia | Blood Glucose, Postprandial | Blood Insulin, PostprandialFinland
-
Lund UniversityAnti-Diabetic Food CentreCompletedPostprandial Blood Glucose RegulationSweden
-
Oslo Metropolitan UniversityUniversity of Oslo; Nofima; Mills DACompletedGut Microbiota | Satiety | Postprandial Blood GlucoseNorway
-
Biofortis, Merieux NutriSciencesLonza Inc.Completed
-
Wageningen UniversityCompletedGlucose Metabolism | Postprandial Glucose ResponsesNetherlands
-
Lund UniversitySwedish Foundation for Strategic ResearchCompleted
-
Northumbria UniversityPlant & food Research LtdCompletedPharmacodynamic Profile of 'Blackadder' Blackcurrant Juice Effects Upon the Monoamine Axis in HumansMonoamine Oxidase Inhibitor Activity | Prolactin Levels | Postprandial Blood Glucose
-
Lund UniversitySwedish Foundation for Strategic ResearchCompleted
-
NestléCompletedPostprandial Glucose ResponseSwitzerland
Clinical Trials on PolyGlycopleX (PGX)
-
Canadian Center for Functional MedicineUniversity of British Columbia; InovoBiologic Inc.CompletedBlood Glucose, Postprandial | Appetite and Hunger, SuppressionCanada
-
Glycemic Index Laboratories, IncCanadian Center for Functional Medicine; InovoBiologic Inc.CompletedBlood Glucose, PostprandialCanada
-
Canadian Center for Functional MedicineUniversity of British Columbia; InovoBiologic Inc.CompletedWeight Loss | Appetite SuppressionCanada
-
InovoBiologic Inc.Terminated
-
Duke UniversityNational Institute of General Medical Sciences (NIGMS)Completed
-
Brigham and Women's HospitalCQuentia NGS, LLCWithdrawnPerioperative/Postoperative ComplicationsUnited States
-
University of MichiganCompletedAntidepressants Causing Adverse Effects in Therapeutic UseUnited States
-
Duke UniversityCompletedPharmacogenetics | Medication Therapy ManagementUnited States
-
Mayo ClinicCompletedGastrointestinal DiseasesUnited States
-
Mayo ClinicNot yet recruitingSide Effect of Drug | Pharmacogenomic Drug Interaction | Drug Metabolism, Poor, CYP2D6-Related | Ineffective Drug Action | Drug Metabolism, Poor, CYP2C19-RelatedUnited States